Literature DB >> 15378775

siRNA-mediated inhibition of HBV replication and expression.

Xiao-Nan Zhang1, Wei Xiong, Jia-Dong Wang, Yun-Wen Hu, Li Xiang, Zheng-Hong Yuan.   

Abstract

AIM: RNA interference (RNAi) is a newly discovered phenomenon provoked by dsRNA. The dsRNA is initially cleaved by Dicer into 21-23 nt small interfering RNA (siRNA) and can then specifically target homologous mRNA for degradation by cellular ribonucleases. RNAi has been successfully utilized to down-regulate the endogenous gene expression or suppress the replication of various pathogens in mammalian cells. In this study, we investigated whether vector-based siRNA promoted by U6 (pSilencer1.0-U6) could efficiently inhibit HBV replication in cell culture.
METHODS: pSilencer vectors with inserts targeting on different regions of HBV genome were constructed. These plasmids were co-transfected with pHBV3.8 into Huh-7 cells via lipofection and viral antigens were measured by ELISA. Viral RNA was analyzed by Northern blot. The mRNA of MxA and 2'-5'OAS was reverse transcribed and quantified by real-time PCR.
RESULTS: Vector-based siRNA could potently reduce hepatitis B virus antigen expression in transient replicative cell culture. Furthermore, Northern blot analysis showed that viral RNA was effectively degraded, thus eliminating the messengers for protein expression as well as template for reverse transcription. Real-time PCR analysis of cellular MxA and 2'-5'OAS gene expression revealed that vector-based siRNA did not provoke the interferon pathway which reassured the specificity of the vector-based RNA interference technique.
CONCLUSION: Our results indicate that RNA interference may be a potential tool to control HBV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378775      PMCID: PMC4576254          DOI: 10.3748/wjg.v10.i20.2967

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 2.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

3.  Short interfering RNA confers intracellular antiviral immunity in human cells.

Authors:  Leonid Gitlin; Sveta Karelsky; Raul Andino
Journal:  Nature       Date:  2002-06-26       Impact factor: 49.962

Review 4.  Dissecting HIV-1 through RNA interference.

Authors:  Mario Stevenson
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

5.  Induction of an interferon response by RNAi vectors in mammalian cells.

Authors:  Alan J Bridge; Stephanie Pebernard; Annick Ducraux; Anne-Laure Nicoulaz; Richard Iggo
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

Review 6.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

7.  RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells.

Authors:  Joyce A Wilson; Sumedha Jayasena; Anastasia Khvorova; Sarah Sabatinos; Ian Gaël Rodrigue-Gervais; Sudha Arya; Farida Sarangi; Marees Harris-Brandts; Sylvie Beaulieu; Christopher D Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

Review 8.  Global control of hepatitis B virus infection.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

9.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

10.  Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses.

Authors:  V Bitko; S Barik
Journal:  BMC Microbiol       Date:  2001-12-20       Impact factor: 3.605

View more
  13 in total

1.  Inhibition of hepatitis B virus expression and replication by RNA interference in HepG2.2.15.

Authors:  Zhong-Fu Zhao; Hui Yang; De-Wu Han; Long-Feng Zhao; Guo-Ying Zhang; Yun Zhang; Ming-She Liu
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

2.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

3.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

4.  Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro.

Authors:  Jason L Starkey; Estelle F Chiari; Harriet C Isom
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

5.  Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts.

Authors:  Lindsey L Snyder; Jonathan M Esser; Catherine J Pachuk; Laura F Steel
Journal:  Antiviral Res       Date:  2008-05-06       Impact factor: 5.970

6.  Combination of small interfering RNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cells.

Authors:  Xiao-Min Xin; Gui-Qiu Li; Ying-Yu Jin; Min Zhuang; Di Li
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

7.  Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.

Authors:  Gui-Qiu Li; Wei-Zhen Xu; Jing-Xia Wang; Wen-Wei Deng; Di Li; Hong-Xi Gu
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

8.  Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression.

Authors:  Jinjian Yao; Weiling Yu; Ying Chang; Jinghua Ren; Dong Xu; Siyuan Han; Jusheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

9.  Criteria for effective design, construction, and gene knockdown by shRNA vectors.

Authors:  Debra J Taxman; Laura R Livingstone; Jinghua Zhang; Brian J Conti; Heather A Iocca; Kristi L Williams; John D Lich; Jenny P-Y Ting; William Reed
Journal:  BMC Biotechnol       Date:  2006-01-24       Impact factor: 2.563

Review 10.  New therapeutics targets in chronic viral cardiomyopathy.

Authors:  W Poller; H Fechner; U Kühl; M Pauschinger; H P Schultheiss
Journal:  Ernst Schering Res Found Workshop       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.